Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab in COVID-19 pneumonia
NCT04386239Phase 1Withdrawn
- Sponsor
- ASST Fatebenefratelli Sacco
- Start
- Jan 2021
- Primary completion
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of sarilumab in coronavirus disease 2019 (COVID-19), sponsored by ASST Fatebenefratelli Sacco. Primary endpoint: Proportion of patients who show an improvement of the respiratory function at 6 weeks. Planned start Jan 2021; status: withdrawn.
02
Drugs
sarilumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04386239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04386239.